|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
21 Hickory Dr, Waltham, Massachusetts 02451, US
|
|
Lucy Therapeutics is offering a differentiated and novel approach to drug discovery by drugging targets associated with early disease pathogenesis. LucyTx’s unique approach recognizes that improvement of mitochondrial function early in disease will lead to disease modification as opposed to late-stage symptomatic treatments being pursued by many others. Mitochondrial improvement effects multiple downstream effectors that are essential to disease initiation and progression. Our targets have been validated as neuroprotective in multiple animal models. Key to our strategy is a novel dosing regimen which will mimic effects known to be protective for both neurological and cardiovascular events implicated in key CNS diseases. LucyTx proposes to focus on the orphan disease Rett Syndrome for a proof of concept; we will also explore applications of our technology to Parkinson’s and other CNS diseases.
|
Lucy Therapeutics Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Lucy Therapeutics email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Lucy Therapeutics customer service number in your country click here to find.
Denise Goode is the CEO of Lucy Therapeutics. Or you may call 7813075212
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.